Bioinvent receives milestone payment as takeda moves mezagitamab into phase 3

Lund, sweden / access newswire / april 8, 2025 / bioinvent international ab ("bioinvent") (nasdaq stockholm:binv), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that it has earned a 1 million usd milestone payment, following takeda's (tse:4502/nyse:tak) initiation of phase 3 clinical trial of mezagitamab (tak-079), identified from bioinvent's proprietary n-coder® antibody library. the study is evaluating this potential best-in-class anti-cd83 monoclonal antibody for persistent or chronic primary immune thrombocytopenia (itp).
TAK Ratings Summary
TAK Quant Ranking